Abstract
BackgroundBiologic disease-modifying anti-rheumatic drugs (bDMARDs) remain inaccessible to a majority of patients in resource-poor countries due to high cost. Cost-saving strategies including the use of generic bDMARDs with an early...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
